Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 11Terminated 4Active not recruiting 3Unknown 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Neoplasm Metastasis 1Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 438Carboplatin 321Nivolumab 293Cyclophosphamide 285Specimen Handling 257Paclitaxel 249Magnetic Resonance Spectroscopy 249Cisplatin 248Radiotherapy 218Dexamethasone 183Gemcitabine 177Biopsy 177durvalumab 169atezolizumab 149Doxorubicin 140Rituximab 138Lenalidomide 135Docetaxel 131Ipilimumab 130Bevacizumab 128Radiation 121Capecitabine 117Etoposide 116Oxaliplatin 114Fluorouracil 110Pemetrexed 109Radiosurgery 108fludarabine 106venetoclax 102Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Interleukin-12 × Clear all
NCT03030378 2026-05-19

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
36 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01468896 2026-04-29

Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
23 enrolled 11 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02483312 2025-12-01

A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)

University Health Network, Toronto

Phase 1 Active not recruiting
9 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡